CFO4Life Group LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,966 shares of the medical research company’s stock after purchasing an additional 195 shares during the quarter. Amgen accounts for 1.1% of CFO4Life Group LLC’s holdings, making the stock its 11th largest position. CFO4Life Group LLC’s holdings in Amgen were worth $1,200,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. MCF Advisors LLC increased its stake in Amgen by 53.3% in the first quarter. MCF Advisors LLC now owns 1,649 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 573 shares during the last quarter. Greatmark Investment Partners Inc. bought a new position in Amgen in the first quarter valued at approximately $217,000. Flinton Capital Management LLC increased its stake in Amgen by 22.4% in the first quarter. Flinton Capital Management LLC now owns 53,550 shares of the medical research company’s stock valued at $8,786,000 after acquiring an additional 9,792 shares during the last quarter. FTB Advisors Inc. increased its stake in Amgen by 809.1% in the first quarter. FTB Advisors Inc. now owns 18,710 shares of the medical research company’s stock valued at $3,062,000 after acquiring an additional 16,652 shares during the last quarter. Finally, Copeland Capital Management LLC increased its stake in Amgen by 21.1% in the first quarter. Copeland Capital Management LLC now owns 55,790 shares of the medical research company’s stock valued at $10,053,000 after acquiring an additional 9,735 shares during the last quarter. 78.20% of the stock is currently owned by institutional investors.

A number of brokerages recently issued reports on AMGN. Royal Bank Of Canada began coverage on shares of Amgen in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $192.00 price objective on the stock. Bank of America Corporation lifted their price objective on shares of Amgen to $210.00 and gave the company a “buy” rating in a research note on Thursday, October 5th. Cann reissued a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research note on Friday, October 6th. Morgan Stanley reissued an “overweight” rating and issued a $196.00 price objective (up from $189.00) on shares of Amgen in a research note on Friday, October 6th. Finally, Mizuho reissued a “buy” rating and issued a $198.00 price objective on shares of Amgen in a research note on Friday, October 6th. Thirteen investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. Amgen presently has a consensus rating of “Buy” and an average price target of $190.03.

WARNING: “CFO4Life Group LLC Acquires 195 Shares of Amgen Inc. (AMGN)” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/11/14/cfo4life-group-llc-acquires-195-shares-of-amgen-inc-amgn.html.

Shares of Amgen Inc. (NASDAQ:AMGN) opened at $171.50 on Tuesday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The company has a market cap of $125,110.70, a PE ratio of 13.70, a PEG ratio of 2.50 and a beta of 1.37. Amgen Inc. has a 52-week low of $138.83 and a 52-week high of $191.10.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm’s revenue for the quarter was down .7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.02 earnings per share. research analysts anticipate that Amgen Inc. will post 12.66 EPS for the current year.

Amgen declared that its board has authorized a stock repurchase program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.68%. The ex-dividend date is Thursday, November 16th. Amgen’s payout ratio is presently 41.63%.

In related news, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.